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Abstract 
 
Cancer stem cells may mediate therapy resistance and recurrence in various types of 
cancer, including glioblastoma. Cancer stem-like cells can be isolated from long-term 
cancer cell lines, including glioma. 
Using sphere formation as a model for cancer cell stemness in vitro, we derived sphere 
cultures from SMA-497, SMA-540, SMA-560 and GL-261 glioma cells. Gene expression 
and proteomics profiling demonstrated that sphere cultures uniformly showed elevated 
expression of stemness-associated genes, notably including CD44. Differences in 
neural lineage marker expression between non-sphere and sphere cultures were 
heterogeneous except for a uniform reduction of β-III-tubulin in sphere cultures. All 
sphere cultures showed slower growth. Self-renewal capacity was influenced by 
medium conditions, but not non-sphere versus sphere culture phenotype. Sphere 
cultures were more resistant to irradiation whereas both non-sphere and sphere 
cultures were highly resistant to temozolomide. Non-sphere cells formed more 
aggressive tumors in syngeneic mice than sphere cells in all models except SMA-560. 
There were no major differences of vascularization or infiltration by T cells or 
microglia/macrophages between non-sphere and sphere cell-derived tumors. 
Mouse glioma cell lines may be induced in vitro to form spheres that acquire features of 
stemness, but do not exhibit a uniform biological phenotype, challenging the view that 
they represent a superior model system. 
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List of abbreviations: CNPase, 2',3'-cyclic-nucleotide 3'-phosphodiesterase; DAB, 3,3′-
diaminobenzidine; DAPI, 4',6-diamidino-2-phenylindole; DMEM, Dulbecco`s modified 
Eagle medium; EDTA, ethylenediaminetetraacetic acid; EGF, epidermal growth factor; 
FACS, fluorescence-activated cell sorting; FC, fold change; FCS, fetal calf serum; FGF, 
fibroblast growth factor; FITC, fluorescein isothiocyanate; GFAP, glial fibrillary acidic 
protein; Gy, Gray; H&E, hematoxylin and eosin; NB, Neurobasal A medium; NS, non-
sphere cultures; P, probability; PBS, phosphate-buffered saline; PE, phycoerythrin; 
PFA, paraformaldehyde; rpm, rounds per minute; SC, sphere (stem-like) cultures; SEM, 
standard error of the mean; SFI, specific fluorescence index; SMA, spontaneous mouse 
astrocytoma; TMZ, temozolomide; βIIIT, beta three tubulin; kDa, kilodalton 
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Introduction 
 
Glioblastomas are highly aggressive intrinsic brain tumors that may develop at all age 
groups, with incidence steadily increasing with age. Despite multimodal treatment of 
surgery followed by radiotherapy and alkylating agent chemotherapy, the median 
survival of glioblastoma patients is still in the range of less than one year in population-
based studies (1). Effective treatments may be impeded by the high morphological, 
phenotypic and genetic cellular diversity. 
A specific subpopulation of tumor cells, variably termed glioma stem cells or glioma-
initiating cells, has been identified in human glioblastomas and has been proposed to 
confer therapy resistance and tumor progression despite multimodal therapy (2-4). 
Glioma stem cells are believed to be responsible for tumor initiation and growth due to 
their unlimited self-renewal capacity and the ability to give rise to more differentiated 
tumor cells in the tumor bulk. Furthermore, they have been proposed to express specific 
DNA damage response proteins as well as drug efflux proteins in response to 
radiotherapy and chemotherapy with DNA alkylating agents such as temozolomide 
(TMZ) (5-7).  
Neural stem cell culture conditions have been used as a standard method to isolate and 
selectively expand glioma stem cells as tumor spheres that resemble neurospheres in 
culture, not only from resected primary gliomas ex vivo, but also from C6 rat and 
U373MG, A172 and U87MG human glioma cell lines (2-4, 8, 9). Reports on the size of 
the cell population isolated from the C6 rat glioma cell line that displayed these stem cell 
characteristics varied from 4% to 87% (9, 10). Similar to neural stem cells, the putative 
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cancer stem cells from glioma cell lines have been shown to be capable of clonal 
growth, to exhibit multi-lineage differentiation potential, and to share the expression of 
various neural stem/progenitor cell markers, including CD133, nestin, Musashi-1 and 
Sox2 (8, 10-13). These neural stem cell characteristics as well as their in vivo 
tumorigenicity are among the criteria used to identify glioma stem cells. 
The best choice of experimental model for glioma research depends on the type of 
scientific question to be addressed (14). GL-261 and SMA cell lines are the most 
commonly used syngeneic mouse glioma models (15-17). Here, we systematically 
addressed the question whether sphere cultures can be derived from these cell lines 
and whether these preferentially exhibit features of stemness, including enhanced self-
renewal, stem cell marker expression, multi-lineage differentiation potential, resistance 
to radiotherapy and chemotherapy, and tumorigenicity in vivo. 
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Materials and Methods 
 
Materials 
TMZ (parental grade 2577461) was kindly provided by MSD Switzerland (Zug, 
Switzerland). Primary antibodies for flow cytometry included: anti-human/mouse CD44 
(working dilution of 1:100) (eBiosciences, San Diego, CA), mouse anti-prominin 
(CD133)-1-phycoerythrin (PE) (1:100) (Miltenyi Biotec, Bergisch Gladbach, Germany), 
mouse IgG2bκ isotype control (eBiosciences), phycoerythrin (PE)-conjugated mouse 
IgG isotype control (BD Biosciences, San Jose, CA), and fluorescein isothiocyanate 
(FITC)-conjugated goat anti-rat IgG (BD Bioscience). The concentrations of isotype 
controls were adjusted to have the same IgG concentration as the specific antibodies. 
For immunofluorescence staining, the following primary antibodies were used: 
monoclonal mouse anti-nestin IgG1 (1:200) (AbD serotec, Düsseldorf, Germany), 
polyclonal rabbit anti-Musashi-1 (1:400) (Chemicon, Zug, Switzerland), polyclonal rabbit 
anti-β-III-tubulin (βIIIT) IgG (1:1000) (Abcam, Cambridge, UK), monoclonal mouse anti-
2',3'-cyclic-nucleotide 3'-phosphodiesterase (CNPase) IgG1 (1:100) (Chemicon), 
polyclonal rabbit anti-glial fibrillary acidic protein (GFAP) IgG (1:1000) (Dako, Baar, 
Switzerland), and monoclonal rabbit anti-Ki-67 IgG (1:100) (Epitomics, Nunningen, 
Switzerland). Alexa Fluor®-488-conjugated goat anti-rabbit IgG (Invitrogen, Basel, 
Switzerland) or anti-mouse IgG (both 1:100) (Invitrogen) were used as secondary 
antibodies. For immunohistochemistry of mouse gliomas in vivo, the following primary 
antibodies were used: anti-human/mouse CD44 (1:1000) (eBiosciences), polyclonal 
rabbit anti-βIIIT IgG (1:1000) (Abcam), rat anti-CD3 (1:1000) (BD Bioscience), anti-
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CD11b (1:1000) (BD Bioscience), anti-CD31 (1:50) (BD Bioscience) and anti-Ki-67 
(1:100) (Epitomics). 
 
Cell culture 
Murine SMA-497, SMA-540 and SMA-560 cells were kindly provided by Dr. D.D. Bigner 
(Durham, NC). GL-261 cells were obtained from the American Type Culture Collection 
(Rockville, MD). These cell lines are commonly cultured as adherent monolayers in 
Dulbecco`s modified Eagle medium (DMEM) (Gibco, Life Technologies, Zug, 
Switzerland) supplemented with 10% heat-inactivated FCS (Biochrom KG, Zug, 
Switzerland) and 2 mM glutamine (Biochrom KG) (DM medium), herein referred to as 
non-sphere cultures. Sphere cultures were generated from non-sphere cultures by 
placing the cells in Neurobasal (NB)-A medium (Gibco) supplemented with 2% B27 
(Gibco), 20 ng/ml basic fibroblast growth factor (FGF) and 20 ng/ml epidermal growth 
factor (EGF) (Peprotech, London, UK), 6.3 U/ml heparin (Sigma, St. Louis, MO), and 2 
mM glutamine (NB medium) at a density of 50,000 cells/ml. Sphere cultures were 
cultured until the 3rd passage prior to use for experiments, with a passage duration of 
approximately 7 days. 
 
Cell growth and doubling times  
Non-sphere (2,000/ml) or sphere (20,000/ml) cells were seeded in 25 cm2 flasks (TPP 
Techno Plastic Products AG, Trasadingen, Switzerland) in their respective medium. 
Every day for non-sphere and every two days for sphere cultures, an aliquot of the cells 
was dissociated into single cell suspensions using TrypLExpress cell dissociation 
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reagent (Gibco), stained with 0.4% trypan blue, and viable cells were counted using 
Neubauer chambers (VWR International AG, Dietikon, Switzerland). Cell counts from 
three separate experiments were obtained.  
 
Limiting dilution assay 
Non-sphere cells were seeded in duplicate in 0.5 ml DM medium in 24 well plates 
(Faust Laborbedarf AG, Schaffhausen, Switzerland) at the following cell numbers per 
well: 250, 83, 28, 9, 3 and 1. Sphere cells were also seeded in duplicate in 0.5 ml NB 
medium at the following cell numbers per well: 1,000, 250, 63, 16, 4 and 1. A colony 
was defined by > 25 non-sphere cells and the numbers of colonies were counted at 4-
14 days. A sphere was defined by > 5 cells and the number of spheres was counted 
after 7-20 days. A 10x solution of growth factors (EGF and FGF) and heparin was 
added to the sphere culture plates to a final concentration of 20 ng/ml of growth factors 
and 6.3 U/ml of heparin, respectively, every week. To assess the plasticity of non-
sphere and sphere cells, the colony-forming and sphere-forming capabilities were also 
assessed in limiting dilution assays after a switch of conditions, that is, by seeding 
sphere cells in DM medium and by seeding non-sphere cells in NB medium at the cell 
numbers indicated above for the respective medium. Results were derived from three 
separate experiments.  
 
Clonogenicity assays 
Non-sphere or sphere cells were seeded at 1,000 cells per well with 5 replicates in 96 
well plates, treated as indicated, and then further cultured until the untreated non-
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sphere cells had formed colonies and the sphere cultures had reached 100-150 µm in 
sphere size. Growth factors were supplemented weekly to the NB medium as described 
above. Then, Alamar Blue (Invitrogen) was added to the plates and incubated for 4 h at 
37°C after which the plates were analyzed using a cytofluorometer (Infinite 200PRO, 
Tecan Group Ltd, Männedorf, Switzerland). Assays were repeated three times. 
Appropriate control experiments had indicated that the Alamar Blue assay is a reliable 
surrogate marker of clone or sphere number, but more convenient for high volume 
pharmacological studies than actual clone or sphere counting. 
 
Flow cytometry 
Cells were harvested and dissociated into single cells by TrypLExpress cell dissociation 
reagent and resuspended in PBS containing 0.5% FCS and 2 mM 
ethylenediaminetetraacetic acid (EDTA) (FACS buffer). Cells were stained with primary 
antibodies for 30 min on ice in the dark. After washing with PBS, cells were 
resuspended in FACS buffer and stained with secondary antibody (when required) on 
ice for 30 min. After staining, cells were washed with PBS, resuspended in FACS buffer 
and analyzed using the Beckman Coulter and Summit 4.3 software (Nyon, Switzerland). 
Staining intensity was expressed as specific fluorescence indexes derived by dividing 
signal obtained with specific as opposed to isotype control antibody. Percentages of 
positively stained cells were measured by setting the gate at 1.3% of the fluorescence 
(represented by the FL 1 log in the histogram) of the isotype control. Similar results 
were obtained from two separate flow cytometric analyses. 
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Immunofluorescence microscopy 
To analyze the expression of neuronal stem cell, mature neuronal and glial cell markers, 
sphere cultures were prepared as cytospin samples whereas non-sphere cultures were 
grown on sterilized 11 mm glass coverslips (Assistent 1001/12) coverslips at 5,000 cells 
in a 24 well plate until they were 80-90% confluent. Spheres that had reached a size of 
150-200 µm in diameter were harvested by centrifugation at 700 rpm for 5 min and 
resuspended in 1200 µl of NB medium. 100 µl of resuspended spheres were cytospun 
using the Cytospin 4 (Thermo Scientific, Wohlen, Switzerland) at 650 rpm for 4 min. 
Cytospun spheres were left to dry for 15 min, fixed and stained as outlined below. Cells 
were washed in PBS and fixed at room temperature for 10 min in either 4% 
paraformaldehyde (PFA) or methanol pre-cooled to -20°C, according to the antibody 
recommendations. After washing, cells fixed in PFA were permeabilized in 0.1% Triton 
X-100 in PBS for 10 min. Cells were then washed and blocked using blocking solution 
(Candor Biosciences, Wangen, Germany) for 25 min. Primary antibodies were prepared 
in antibody dilution buffer (DCS Innovative Diagnostik System, Hamburg, Germany). 
Cells were stained with primary antibodies for 90 min. Following staining, cells were 
washed in PBS and stained using secondary antibodies prepared in antibody dilution 
buffer for 30 min. Cells were then stained with 1 µg/ml 4',6-diamidino-2-phenylindole 
(DAPI) (Invitrogen) at a working dilution of 1:1000 in antibody dilution buffer for the last 
10 min. Finally the cells were washed in PBS and mounted on microscope slides 
(Superfrost plus, Thermo Scientific) using fluorescent mounting medium (Dako). 
Analysis was performed using the SP5 laser scanning confocal microscope (Leica, 
Wetzlar, Germany) and LAS-AF Lite software. Positively stained cells were identified by 
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setting the fluorescence signal intensity used for the positive control for each antibody 
staining under saturation levels. The P19 neuronal progenitor cell line was used as a 
positive control for nestin and Musashi-1, cryosections of wild type C57BL/6 mouse 
brain were used as positive control for GFAP, βIIIT and CNPase. 
 
Irradiation 
Cells were seeded in 0.5 ml medium into 24 well plates for limiting dilution or 96 well 
plates for clonogenic survival assays. On the next day the plates were irradiated at 0, 1, 
3 or 9 Gy using a Co source (Gebrüder Sulzer, Thermische Energiesysteme, 60-Co, 
Winterthur, Switzerland). Cells were allowed to grow and colonies or spheres were 
counted at 4-14 days after seeding when colonies of at least 25 non-sphere cells had 
formed or at 7-20 days after seeding when spheres of at least 5 sphere cells had 
formed, alternatively, Alamar Blue assays (Invitrogen) were performed. 
 
TMZ exposure 
Cells were seeded in 0.5 ml of their respective medium and plated into 24 well plates for 
limiting dilution assays or 96 well plates for clonogenic survival assays. On the next day 
the cells were treated with 0 (serum-free), 10, 100 or 1000 µM TMZ diluted in serum-
free DM medium or complete NB medium for 24 h. After that the cells were cultured in 
fresh complete DM or NB medium and allowed to grow. Colonies or spheres were 
counted, or Alamar Blue assays were performed as described above. 
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In vivo experiments 
The standard operating procedure and the treatment of all animals were according to 
the Swiss Cantonal Veterinary office regulations under the Animal license permission 
number 95/2009 and 235/2012. Following anesthesia a burr hole was drilled in the skull 
2 mm lateral to the bregma. The needle of a Hamilton syringe (Hamilton, Darmstadt, 
Germany) was introduced to a depth of 3 mm. A volume of 2 µl of PBS single cell 
suspension was slowly injected into the right striatum. 1,000 non-sphere or sphere cells 
of SMA-497, SMA-540 or SMA-560 cell lines were implanted into 6 groups of 11 mice 
per group of VM/Dk mice. Similarly, GL-261 cells were implanted in 2 groups (non-
sphere and sphere cells) of 10 mice per group in C57Bl/6 mice. Two mice per group 
were euthanized using a pre-randomization scheme when any mouse in the experiment 
became symptomatic in order to perform histological studies to assess tumor growth at 
an early stage (Table 1). The other 9 mice (8 mice for the GL-261 model) were 
euthanized when displaying neurological symptoms and were thus used for survival 
analysis (pooled from two separate experiments) and these along with the rest of the 
brains collected at termination of the experiment, day 80 after implantation, were used 
for further immunohistochemical stainings. All brains collected upon euthanization were 
embedded in cryomoulds in Shandon Cytochrome yellow (Thermo Scientific) and frozen 
in liquid nitrogen. Tumor incidences were determined using hematoxylin and eosin 
stainings of 8 mm thick cryosections cut using the Microm HM560 (Microchom HM560, 
Thermo Scientific) before constructing and analyzing Kaplan Meier survival curves 
using the log-rank test in GraphPad Prism 5.0 software. 
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Immunohistochemical analysis 
Cryosections were fixed in ice-cold acetone for 10 min, washed in PBS and treated with 
3% hydrogen peroxide for 10 min. The sections were then washed and blocked using 
blocking solution (Candor Biosciences). After blocking the primary antibodies were 
applied overnight at 4°C. Next, the sections were washed and probed using biotinylated 
rabbit-anti-rat secondary antibody (Vector) for 30 min at room temperature. The antigen 
antibody conjugates were then detected by staining with 3,3′-diaminobenzidine (DAB) 
(Dako) for 1-3 min. The nuclei were stained using hematoxylin for 4 min, washed in 
water and dehydrated twice in 96% ethanol, then twice in 100% ethanol and three times 
in xylol before mounting onto coverslips using Eukitt mounting medium. Quantification of 
proliferating cells (Ki-67), blood vessel density (CD31), T cells (CD3) and microglial 
cells/macrophages (CD11b) was obtained from 4-6 different areas (depending on tumor 
size) from 3 tumors each at the terminal stage in an area of 0.35 mm2. βIIIT and CD44 
levels were not quantified. Statistical significance was calculated using the paired 
student t-test. 
 
Analysis of gene expression and proteomics data 
The generation of transcriptomic and proteomic data is reported in detail in the 
Supplementary Note. Raw microarray data were calibrated and summarized using the 
RMA method including quantile-normalization (18, 19). The expression value of each 
gene was transformed into log10-scale and centered with respect to its mean value 
averaged over all samples investigated (20). A relative log expression value of zero 
indicates that the gene is expressed according to its mean expression value, while 
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positive and negative values refer to over- and under-expression in the data set, 
respectively. 
Gene expression was analysed using the portraying method based on self-organizing 
map (SOM) data compression. This approach transforms the gene expression patterns 
of more than 20,000 genes per sample into intuitive quadratic mosaic portraits 
representing 50x50 grids, in which each tile refers to one microcluster of concertedly 
expressed genes called ‘metagene’ (20, 21). Further analyses were performed either in 
metagene space, e.g., by clustering concertedly expressed metagenes into so-called 
spot modules, by calculating group-averaged mean portraits for each cell line and 
sample condition, or by selecting differential features by calculating difference portraits 
(Suppl. Fig. 1,2) or based on single gene expression data, e.g., by applying gene set 
enrichment analysis for functional interpretation. The latter approach makes use of the 
gene set enrichment score (GSZ) which estimates the significance of differential 
expression of the members of a set of genes compared with the mean expression of all 
genes in a sample (22). Gene sets were taken from standard gene ontology (GO) 
categories or from previous publications as indicated below. All analyses were 
performed using the R-program opoSOM providing basic SOM portraying in 
combination with a series of data mining methods and comprehensive visualization 
options (20) (22). 
Protein data were processed using the same analysis pipeline as described above for 
gene expression data except for RMA calibration, i.e., the data were log-10 
transformed, centralized and subsequently analyzed using the SOM-portraying method. 
Suitability of this method for analyzing proteomics data was recently demonstrated (23). 
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 Statistical analysis 
For the functional assays, data are usually representative of experiments performed 
three times with similar results. Statistical significance for the clonogenicity studies after 
irradiation or TMZ treatments was assessed with a two-way ANOVA test using the 
GraphPad Prism 5.0 software. Statistical analysis of cell doubling time and 
immunofluorescence was calculated using two-tailed student t-test with equal variance 
while immunohistochemistry data were analysed using two-tailed student t-test with 
unequal variance, due to the heterogeneous nature of tumors. Survival statistics in the 
in vivo studies were calculated using the log-rank test from the GraphPad Prism 5.0 
software. 
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Results 
 
Gene expression and proteomics profiling of sphere versus non-sphere cultures of 
murine glioma cells in vitro 
Sphere cultures were established from non-sphere cultures of all four mouse glioma cell 
lines by switching the non-sphere cultures to NB medium, which resulted in sphere 
formation in all cell lines (Fig. 1A). These spheres could be maintained for months under 
these culture conditions. Microarray-based mRNA expression profiling and mass 
spectrometry-based proteome analyses were done to assess the gene activity in terms 
of mRNA and protein abundance, respectively (Supplementary Note). The primary 
analysis was performed by comparing the expression portraits of all sample classes, 
i.e., cell lines and culture conditions, obtained from the transcriptome and proteome 
data, respectively. In contrast to the light microscopic features which were dominated by 
the culture conditions, the molecular expression landscapes were mainly governed by 
the respective cell line (Fig. 1B). For example, each of the SMA lines showed similar 
gene expression largely independent of the non-sphere or sphere culture condition, 
reflected also in the similarity tree based on mRNA expression profiles, which also 
outlines that SMA-560 is less related to the other two, more related SMA lines (Suppl. 
Fig. 3). The proteomic portraits supported this observation for GL-261 whereas the 
proteomics portraits of the SMA samples revealed clear differences between the sphere 
culture and non-sphere culture conditions (Figure 1D, E, Suppl. Fig. 4). Non-sphere 
cultures of the SMA lines were similar whereas GL-261 exhibited a different proteomics 
profile. Thus, altogether, the similarities between paired non-sphere and sphere cultures 
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were higher than among non-sphere versus sphere cultures, irrespective of whether 
GL-261 was included or excluded from the analyses. 
 
Expression of stemness markers 
Next we performed differential analyses between the samples cultured under non-
sphere versus sphere conditions (Suppl. Fig. 1,2). Both transcriptomics and proteomics 
data revealed a cluster of mRNA and proteins concertedly down-regulated in non-
sphere and upregulated in sphere cultures, depicted as spot profiles in Fig. 1C,E). 
Selected sets of human embryonic stem cell marker genes (24) were selectively up-
regulated in sphere cultures at mRNA level and even more clearly at protein level (Fig. 
2). No such changes were observed for other marker sets (data not shown). Changes in 
stem cell marker expression induced by sphere formation were often not uniform: 
Notch1 mRNA was up-regulated in SMA-560 (expression fold change, FC=1.8, p=0.06), 
Sox2 mRNA in SMA-497(FC=1.8, p=0.05), SMA-540 (FC=2.2, p=0.005) and SMA-560 
(FC=3.3, p=0.001), and α6-integrin mRNA in SMA-497 (FC=3.1, p=0.04). α6-integrin 
protein was increased in SMA-497 (FC=1.5, p=0.07), SMA-540 (FC=1.5, p=0.02) and 
SMA-560 (FC=1.8, p=0.03). CD44 induction as a marker of stemness in sphere cultures 
was confirmed by flow cytometry (Fig. 3A). Apart from SMA-497 non-sphere and sphere 
cultures, the mouse glioma cell lines were negative for CD133, and CD133 expression 
decreased when SMA-497 cells were shifted to sphere culture conditions (Fig. 3B). 
There was also heterogeneous expression of a third stem cell marker, nestin, among 
non-sphere and sphere cultures: nestin expression decreased in SMA-540 (P=0.0047), 
increased by trend in SMA-560 (p=0.16), and remained similar in the other two cell lines 
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(Fig. 3C,D). Finally, Musashi1 was highly expressed in 3 of the 4 cell lines and 
essentially unaffected by switching from non-sphere to sphere culture conditions (Fig. 
3E,F). 
 
Expression of markers of neuroglial differentiation markers 
The non-sphere cultures expressed neuroglial differentiation markers at variable levels 
by immunofluorescence microscopy. The astrocytic marker GFAP was highly expressed 
in SMA-497 and SMA-560, to a lesser degree in GL-261, but not in SMA-540 (Fig. 
4A,B). The neuronal marker βIIIT was expressed in the SMA lines, but only at very low 
level in GL-261 (Fig. 4C,D). In contrast, the oligodendroglial marker CNPase was 
almost uniformly expressed (Fig. 4E,F). The percentages in Fig. 4B,D,F illustrate that 
many cells co-expressed different markers of the different neuroglial lineages. We then 
determined whether induction of the sphere culture phenotype was associated with 
decreased expression of these markers. GFAP increased under sphere culture 
conditions in SMA-540 (P=0.0007) and by trend in GL-261 (P=0.18), whereas CNPase 
remained highly expressed throughout. Only βIIIT expression uniformly decreased when 
the cells were induced to undergo sphere formation at the following significance levels: 
SMA-497 (P=0.0009), SMA-540 (P= 0.034), SMA-560 (P=0.13) and GL-261 (P=0.093). 
 
Cell growth and clonogenicity of non-sphere versus sphere cultures  
Non-sphere cultures of the SMA cell lines had shorter doubling times than sphere 
cultures at the indicated significance levels: SMA-497 (P=0.03), SMA-540 (P=0.025), 
SMA-560 (P=0.028). The difference was not significant in GL-261 cells (P=0.067) 
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(Suppl. Fig. 5A-C). Also, quantification of Ki-67 immunolabeling, a proliferation marker, 
confirmed higher proliferation of non-sphere cultures for SMA-497 (P=0.019), SMA-540 
(P=0.005) and SMA-560 (P=0.015), but not for GL-261 (P=0.3) (Suppl. Fig. 5D-E). The 
GSZ score of the gene set ‘cell division’, taken from the collection of gene ontology 
(GO) terms ‘biological process’, in all systems studied confirmed this result at least by 
trend at the proteomics level: non-sphere conditions were associated with increased 
activities of the respective genes (Suppl. Fig. 5F). 
Next we assessed the ability for self-renewal in the form of adherent colonies for non-
sphere cells or of sphere formation for sphere culture cells, using limiting dilution 
assays. At similar seeding densities, all non-sphere cultures were superior at self-
renewal to sphere cultures in their respective native culture conditions (Fig. 6A-D). To 
distinguish between impact of “cell type” (non-sphere versus sphere cultures) and 
impact of cell culture conditions (DM versus NB), we performed medium switch 
experiments in that the non-sphere cells were seeded and cultured in NB medium and 
the sphere cells in DM medium in the limiting dilution assays. These experiments 
demonstrated that the DM medium promoted colony formation of sphere cells whereas 
the colony forming capacity of non-sphere cells diminished to those of sphere cultures 
when maintained in NB medium (Fig. 6E-H). 
 
Differential sensitivity of non-sphere versus sphere cultures to irradiation or TMZ 
We next explored the differential sensitivity of non-sphere versus sphere cultures to 
single fractions of irradiation at 1, 3 or 9 Gy (Fig. 7) or to increasing concentrations of 
TMZ (Fig. 8). Effects on survival and reproliferation as well as self-renewal properties 
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were assessed using clonogenic survival and limiting dilution assays. Proliferation of all 
cell lines was only affected at 9 Gy. Non-sphere and sphere cultures of SMA-497 and 
SMA-560 were affected similarly whereas SMA-540 sphere cultures (P=0.26) and GL-
261 non-sphere cultures (P=0.003) were relatively more radiosensitive (Fig. 7A-D). Self-
renewal of non-sphere cultures of all cell lines was more affected than that of sphere 
cultures across the full range of cell numbers seeded (Fig. 7E-H). Similar assays were 
performed to study the effect of TMZ. All cell lines were highly resistant to TMZ. At the 
highest TMZ concentration, the SMA-497 and SMA-540 non-sphere cells were more 
sensitive than the sphere cells, but not to a significant extent. In contrast, no difference 
between non-sphere and sphere cultures emerged for SMA-560 or GL-261 (Fig. 8A-D). 
The self-renewal capacities of non-sphere and sphere cultures after exposure to TMZ at 
100 µM were unaffected in all four cell lines at all seeding densities (Fig. 8E-H). 
 
Tumorigenicity in syngeneic mice 
In order to compare tumorigenicity in vivo, 1,000 non-sphere or sphere cells were 
injected into the right striatum of syngeneic VM/Dk mice for the SMA cell lines or of 
C57Bl/6 mice for GL-261 cells. In 3 of 4 cell lines, non-sphere cell implantation 
produced higher tumor incidences and shorter survival times than sphere cell 
implantation: the significance levels for the differences of the estimated median 
survivals were: SMA-497 (P<0.0001), SMA-540 (P=0.0026) and GL-261 (P=0.0005) 
(Fig. 5A,B,D). Only in the SMA-560 cell line did the sphere cell-derived tumors kill the 
animals earlier than non-sphere cell-derived tumors (P<0.0001) (Fig. 5C). Accordingly, 
when early stages of tumor development were assessed around day 14 in the SMA and 
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at day 29 in the GL-261 models, non-sphere cells of SMA-497 and SMA-540 and 
sphere cells of SMA-560 had already developed large tumors and mice were severely 
symptomatic. Tumors were rather large in GL-261 in both groups at day 29 when the 
mice became symptomatic (Table 1). Further tumor progression did not necessarily 
result in tumors with increased diameters in all groups, but instead was associated with 
multifocal tumor formation that crossed the midline to invade into the contralateral 
hemisphere. Hematoxylin and eosin stainings of all tumors at the terminal stage 
revealed a densely packed mass of pleomorphic cells. Apart from SMA-497 sphere cells 
which did not form a solid primary tumor, but grew diffusely from the beginning, the 
other non-sphere and sphere cells formed a solid lesion from which streams of tumor 
cells and single cell infiltration into normal tissue evolved, resulting in secondary tumors 
and proliferation around perivascular spaces distant from the primary lesion (Suppl. Fig. 
6). The largest tumor diameters and highest incidence of multifocal lesions were seen in 
the SMA-540 non-sphere and GL-261 sphere cell tumors. In end-stage tumors, 
proliferation assessed by Ki-67 labeling was similar in sphere and non-sphere cell-
derived tumors in SMA-497, but increased in sphere cell-derived tumors of SMA-560 
and GL-261. Ki-67 labeling was localized mainly at the periphery of SMA-497 non-
sphere cell tumors whereas both non-sphere and sphere cell tumors in the other cell 
lines had a uniform distribution of proliferating cells within the tumor.  
CD44 and βIIIT levels were assessed to explore whether some of the differences 
between non-sphere and sphere cultures in vitro were maintained when these cells 
were passaged in vivo. This was not the case since CD44 was uniformly expressed in 
all non-sphere and sphere culture tumors, but not in adjacent brain. In contrast, βIIIT 
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was barely detectable in the tumors, but strongly expressed in normal brain, 
corresponding to the sphere culture rather than the adherent phenotype in vitro. CD31 
labeling reflecting vessel density was similar in both non-sphere and sphere cell tumors 
of all cell lines, with significantly higher vessel density seen in the sphere cell group only 
in SMA-560. The SMA-560 tumors were also the most vascularized of all models in 
general. CD3-labeled T cells were found localized at the tumor periphery (Suppl. Fig. 
6A) and in perivascular regions (Suppl. Fig. 6C). They were present at higher levels in 
non-sphere tumors of the SMA models and in the sphere tumors of GL-261. CD11b 
infiltration was more prominent in non-sphere than in sphere cell tumors in the SMA 
models, but not in GL-261 where sphere cell tumors showed higher infiltration. It was 
found within the tumors and outside the tumor (Suppl. Fig. 6C) and sometimes in higher 
densities in areas surrounding blood vessels in GL-261 tumors (Suppl. Fig. 6D). Overall 
there was no association of the extent of immune cell infiltration with outcome. 
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Discussion 
 
The notion that cancers, although of monoclonal origin, are heterogeneous and not 
composed of a monomorphic population of cells is now widely accepted. Various 
approaches have been used to characterize and derive a population of cancer stem 
cells from various types of tumors, including brain tumors, in particular glioblastoma. 
These cancer stem cells have been considered an often quiescent, slowly proliferating 
pool of cells exhibiting resistance to conventional modes of non-surgical therapies, that 
is, irradiation or genotoxic pharmacotherapy. Stem cells have not only been isolated 
from freshly resected tumors ex vivo, but have also been derived from long-term glioma 
and other cancer cell lines, and have been proposed to serve as superior model 
systems to study biology of disease in terms of preserving the invasive phenotype and 
genomic profile of the original tumor (4, 25-27). 
Here we addressed the usefulness of stem cells defined by their sphere-forming 
capacity in a panel of four long-term mouse glioma cell lines. SMA-497, SMA-540 and 
SMA-560 cells were generated from a spontaneous murine astrocytoma detected in a 
VM/Dk mouse (15, 17). GL-261 cells were derived from a tumor generated by 
implantation of methylcholanthrene pellets in C57Bl/6 mouse brains (16, 28). Their 
neuroglial origin was confirmed here by the differential, often co-expression of neuroglial 
lineage markers such as GFAP, βIIIT and CNPase (Fig. 4). We found that even after 
decades of passaging under differentiating (serum-containing) culture conditions, all 
mouse glioma cell lines had retained the plasticity to grow in spheres with the option of 
long-term expansion (Fig. 1A). The sphere culture transcriptomes were uniformly 
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enriched in some stemness-associated genes, including CD44, and such changes from 
non-sphere to sphere cultures were mostly confirmed at the proteome level. 
Up-regulation of one candidate stem cell marker, CD44, a cell surface adhesion protein 
thought to play a role in tumor progression, has been associated with increased 
histopathological grade and poorer prognosis in human gliomas as well as increased 
cell migration and invasiveness in A172 glioma cells (29, 30). In addition, the expression 
of CD44 in glioma stem cells has been shown to be controlled by the transforming 
growth factor-β signalling pathway, which is a target for glioma therapy because of its 
role in tumor growth (31). Here, CD44 expression increased in 3 of 4 cell lines under 
sphere culture conditions, but CD44 was almost lost when SMA-540 were induced to 
assume a sphere culture phenotype (Fig. 3A). The classical glioma stem cell marker 
CD133, which is increasingly questioned regarding its usefulness to delineate stem cells 
of human glioblastomas (32-34), did not distinguish between sphere and non-sphere 
cultures in this panel of mouse glioma cell lines (Fig. 3B). Finally, neither nestin nor 
Musashi-1 expression correlated with the non-sphere versus sphere culture phenotype 
(Fig. 3C-F). Importantly, our study does not challenge the value of any of these markers 
to detect stemness because we do not propose that the sphere cultures generated by 
changing the culture conditions should be considered stem-like. 
GFAP, βIIIT and CNPase are commonly used as markers of astrocytic, neuronal, and 
oligodendroglial differentiation, although GFAP expression is also a radial glial neural 
stem cell marker (35). Our analysis of differentiated neural and glial markers showed 
that sphere culture conditions did not exclusively enrich for a less differentiated, stem-
like phenotype, as previously observed (36), as evidenced by the expression of GFAP 
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and CNPase. Of note, the anti-CNPase antibody used here recognizes both the 46kDa 
CNPase isoform, present in mature oligodendrocytes, and the 48kDa, both of which 
were found to be expressed in oligodendrocyte precursor cells in the normal rat brain as 
well as in C6 glioma cells (37, 38). By contrast, sphere cultures of all cell lines showed 
decreased expression of the mature neuronal marker βIIIT (Fig. 4). 
We find that sphere cultures have slowed growth, which we attribute to the deprivation 
of serum-derived mitogenic stimuli (Suppl. Fig. 5). Unexpectedly, sphere cultures from 
all four cell lines displayed lower self-renewal capacity than non-sphere cultures in 
limiting dilution assays. Medium switch experiments disclosed that the type of medium 
rather than a stable sphere culture versus non-sphere trait conferred the increased self-
renewal (Fig. 6).  
Relative resistance to radiotherapy and chemotherapy, the principal treatment 
modalities for human glioblastoma patients (39), is a conceptual hallmark of glioma 
stem cells. Putatively related to slowed growth kinetics, sphere cultures were uniformly 
less radiosensitive than non-sphere cultures (Fig. 7), but both sphere and non-sphere 
mouse glioma cell cultures were resistant to clinically relevant concentrations of TMZ 
(Fig. 8). 
Recent studies have highlighted the limitations of using sphere culture conditions to 
enrich for cancer stem cells (36, 40). In vivo studies indicated that sphere cells with low 
self-renewal capacity in vitro generated rapidly developing tumors with higher 
penetrance compared to more ‘stem-like’ cells that possessed higher in vitro self-
renewal capacity (41). Using a limiting cell implantation number approach in order to 
critically assess the tumorigenicity of sphere cultures versus non-sphere, we find that 
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sphere cultures were not enriched in cells with higher tumorigenic potential in vivo (Fig. 
5). In fact, non-sphere cultures were more tumorigenic in all but the SMA-560 cell line. 
Moreover, we did not observe stable morphological phenotypes defined by proliferative 
activity or vascular density that would have allowed distinguishing between non-sphere 
and sphere cell-derived tumors derived from the same cell line, suggesting that the 
differential culturing in vitro confirmed differential properties for initial seeding and 
growth in vivo, but did not produce genuinely different tumors. Thus, living in a sphere 
rather than as a monolayer in vitro is a state rather than a trait of a mouse glioma cell. 
Accordingly, the differences in CD44 expression between non-sphere and sphere 
cultures were not maintained in vivo, and, interestingly, the loss of βIIIT in vivo may 
indicate that sphere cultures are closer to the in vivo situation than non-sphere cultures. 
Furthermore, there also seemed to be no difference in immune responsiveness and 
host cell infiltration defined by the numbers of CD3-positive T cells or of CD11b-positive 
cells, possibly representing myeloid suppressor cells. 
In conclusion, this study provides an extensive characterization of the most commonly 
used syngeneic mouse glioma models that should guide researchers in selecting such 
models for their studies. We find no evidence that studies performed with sphere 
cultures derived from long-term cell lines are biologically more meaningful than studies 
performed using standard monolayer cultures, at least in the investigated mouse glioma 
lines. Future studies may need to define whether this holds true for other glioma cell line 
model systems, too. Importantly, our data must not be used to argue against the 
increasing use of human stem-like tumor cell lines immediately derived from freshly 
resected tumor specimens.  
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Figure legends 
 
Figure 1. Gene expression and proteomic profiling of sphere cultures derived 
from longterm mouse glioma cell lines in vitro. A. Light microscopic features under 
non-sphere and sphere culture conditions. B,C. Expression profiling: mean SOM gene 
expression portraits of the cell lines cultured under non-sphere or sphere conditions and 
of the cell line-specific difference between non-sphere and sphere cultures. The ellipses 
in the difference portrait of SMA-540 indicate clusters of genes (so-called 'spots') 
differentially expressed beween non-sphere and sphere cultures (B). Their expression 
levels in the different samples are shown as barplots in C. D,E show the corresponding 
results for proteomics (NS, non-sphere cultures, SC sphere cultures). 
 
Figure 2. Stem cell marker expression: gene expression and proteomic profiling. 
Gene set enrichment analysis using stemness-related genes (24) shows profiles of the 
enrichment score for three gene sets in all cell systems studied. The sets contain genes 
differentially upregulated in hESC9 (A, set hESC9), abundant in hESC (B, hESC10) and 
myc-regulated targets (C, myc2) (NS, non-sphere cultures, SC sphere cultures). 
 
Figure 3. Stem cell marker expression: candidate approach. A,B. CD44 (A) or 
CD133 (B) expression were assessed by flow cytometry (CD44/CD133, black lines; 
isotype control, grey lines, representative of experiments done twice with similar 
results). SFI and percentages of positive cells are indicated in the right upper corner of 
each graph. C-F. Nestin (C,D) or Musashi-1 (E,F) expression were determined by 
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immunofluorescence microscopy and quantified based on DAPI counterstaining from 
three separate stainings (*P<0.01, paired t-test with equal variance) (size bars in C and 
E correspond to 50 µm) (NS, non-sphere cultures, SC sphere cultures). 
 
Figure 4. Neuroglial differentiation marker expression. Immunofluorescence 
microscopy was used to assess GFAP (A,B), βIIIT (C,D), or CNPase (E,F) expression 
(non-sphere grey bars, sphere black bars; size bars correspond to 50 µm). Quantitative 
analysis displays the mean and standard deviation from three experiments (*P<0.05, 
***P<0.001, paired t-test with equal variance) (NS, non-sphere cultures, SC sphere 
cultures). 
 
Figure 5. Tumorigenicity of non-sphere versus sphere cells in vivo. A-D. 1,000 
non-sphere or sphere cells were implanted into the right striatum of syngeneic mice and 
the mice were monitored for survival. Results were pooled from two separate 
experiments (***P<0.001, **P<0.01 by log rank test) (NS, non-sphere cultures, SC 
sphere cultures).  
 
Figure 6. Clonogenicity and spherogenicity of non-sphere versus sphere cells in 
vitro. Colony numbers of non-sphere cultures (open squares, dotted lines) or sphere 
numbers of sphere cultures (black circles, straight lines) were obtained from 3 limiting 
dilution assays at 4-14 days after seeding either in their native medium (DM medium for 
non-sphere and NB medium for sphere cultures (A-D) or in switched medium (non-
sphere cells in NB medium and sphere cells in DM medium) (E-H). 
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 Figure 7. Radiosensitivity of non-sphere versus sphere cells in vitro. A-D. The 
effect of 0, 1, 3 and 9 Gy of ionizing irradiation on the proliferation of non-sphere (open 
squares, dotted lines) versus sphere (filled circles, black lines) cells was assessed by 
irradiating 1,000 cells plated on 96 well plates and allowing them to recover for 5-14 
days in three separate experiments. Assays were stopped when untreated cells became 
confluent. Quantification of cell density was done by Alamar blue staining. E-H. Limiting 
dilution assays after irradiation at 0 (open squares, dotted line for non-sphere cells, 
open circle continuous line for sphere cells) or 9 Gy (closed square, dotted line for non-
sphere cells, closed circle, continuous line for sphere cells) were performed. Colonies or 
spheres were counted 7-20 days after irradiation (n=3, *P<0.05, ***P<0.001, 2 way 
ANOVA) (NS, non-sphere cultures, SC sphere cultures). 
 
Figure 8. Sensitivity to TMZ of non-sphere versus sphere cells in vitro. A-D. The 
effect of increasing concentrations (0, 10, 100, 1,000 µM) of TMZ on the proliferation of 
non-sphere cells (open squares, dotted lines) versus sphere cells (filled circles, black 
lines) was assessed by treating 1,000 cells plated on 96 well plates and allowing them 
to recover for 5-14 days (A-D). Assays were stopped when untreated cells became 
confluent. Quantification was done by Alamar blue staining (n=3). E-H. Limiting dilution 
assays after exposure to 100 µM TMZ (closed square, dotted line for non-sphere cells; 
closed circle, continuous line for sphere cells) were performed and plotted against 
serum-free control (open squares, dotted line for non-sphere cells, open circle 
continuous line for sphere cells). Colonies or spheres were counted 4-20 days after 
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seeding (n=3, *P<0.05,** P<0.01, ***P<0.001, 2 way ANOVA test) (NS, non-sphere 
cultures, SC sphere cultures). 
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Table 1. Characterization of non-sphere and sphere cell-derived tumors in vivo.a 
 
 
      SMA-497 SMA-540 SMA-560 GL-261 
 
Non-sphere Sphere Non-sphere Sphere Non-sphere Sphere Non-sphere Sphere 
Early stage         
Median survival (mean±SEM) 14±0.13 >80 >80 >80 >80 15±0.15 35±0.53 73±2.2 
Tumor incidence n/all (%) 23/23 (100) 1/7 (14) 3/7 (43) 0/7 (0) 2/4 (50) 13/14 (93) 4/4 (100) 4/4 (100) 
Tumor diameter (mm) 2.8±0.1 0.17 0.7±0.04 n/a 0.85±0.11 3.9±0.20 3±0.49 3.7±0.35 
Late stage         
Tumor incidence n/all (%) n/a 5/14 (36) 9/16 (56) 1/16 (6) 6/13 (46) None 8/16, 50 8/14, 57 
Mean tumor diameter (mm) n/a 1.6±0.05 3.9±0.32 3.7 2.9±0.5 n/a 4.0±0.21 3.1±0.31 
Infiltration into contralateral 
hemisphere yes no  yes no no Yes yes yes 
Multifocal tumors (multifocal / 
total tumors, (%)) 6/20, 30 0 3/8, 37.5 0 no 4/18, 22.2 4/18, 22.2 5/18, 27.8 
Ki-67 mean ± SEM (%) 27.7±5.8  23.2±0.76 62.1±1.68 42.1±4.75 55.6±1.67 68.9±5.4* 30.6±3.71 50.2±3.56 * 
  P=0.43    P=0.019  P=0.032 
Ki67 distribution within tumor more at edge  n/a tumor too small uniform uniform uniform Uniform uniform uniform 
CD31 count (mean±SEM) 42.8±2.97 44.4±2.62 41.5±1.63 39±0.49 86±2.59 97.3±4.32* 47±2.05 44.6±2.91 
 
  P=0.70    P=0.011  P=0.20 
CD3 count(mean±SEM) 451±69.7 155±40.1*** 88.4±36.6 67.5±36.3 122±46.3 113±41.1 178±23.9 359±51.3** 
  P=0.00036    P=0.07  P=0.03 
CD11b count (mean±SEM) 1816±159 1015±142** 1927±180 1436±76 1386±133 1048±56 783±68 1334±139* 
  P=0.0014    P=0.14  P=0.032 
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a SMA-497 non-sphere and SMA-560 sphere groups reached the terminal stage at day 14 (early stage) after implantation. To assess tumor morphology at 
progression, two to three mice per group were sacrificed in the other SMA groups. Results from 2 pooled experiments are included. Two mice per group were 
also sacrificed in the GL-261 studies at the occurrence of first symptoms on day 29. The remainder of the data included tumors that developed after day 14 up to 
and including the termination of the experimental day 80 after implantation (late stage). Quantitative data for Ki-67 stained cells is represented as the mean 
percentage of positive cells of the total along with the standard error of the mean (SEM) values. Quantification of blood vessel density (CD31), T cells (CD3) and 
microglial cells/macrophages (CD11b) is expressed as the mean and SEM of positively labeled cells (*P<0.05, **P<0.01, ***P<0.001, paired t-test with unequal 
variance due to heterogeneity within tumor areas). For all immune-labeled stainings, the cells were counted from 4-6 different areas (depending on tumor size) 
within the tumor from 3 different tumors (with the exception of the SMA-540 subline) each at the terminal stage in an area of 0.35 mm2. All counts from all animals 
were derived to obtain mean and SEM. SMA-540 sphere cells were least tumorigenic. Because of the occurrence of only one incidence of tumor, statistical 
comparison between the non-sphere and sphere groups could not be made for all stainings done. 
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